or Try an Advanced Search...

    Technical Analysis for AKTX - Akari Therapeutics Plc

    Grade Last Price % Change Price Change
    F 1.17 -3.62% -0.04
    AKTX closed up 7.92 percent on Thursday, April 18, 2024, on 68 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Apr 29
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Down
    Historical AKTX trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction -3.62%
    Wide Bands Range Expansion -3.62%
    Oversold Stochastic Weakness -3.62%
    New 52 Week Low Weakness 4.01%
    Wide Bands Range Expansion 4.01%
    Down 3 Days in a Row Weakness 4.01%
    Gapped Down Weakness 4.01%
    Oversold Stochastic Weakness 4.01%
    Wide Bands Range Expansion 0.93%
    Oversold Stochastic Weakness 0.93%
    Older End-of-Day Signals for AKTX ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 3 hours ago
    Down 5% about 3 hours ago
    Down 3% about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    Down 2 % about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    AKTX Chart by TradingView
    Basic chart:

    Profile

    Akari Therapeutics Plc Description

    Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Organ Systems Rare Diseases Inflammatory Diseases Autoimmunity Autoimmune And Inflammatory Disease Complement System Myasthenia Gravis Myasthenia Acquired Hemolytic Anemia Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria C5a Hemolytic Uremic Syndrome Sjögren's Syndrome

    Is AKTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
    Apr 1 Akari Therapeutics Insider Ups Holding By 69% During Year
    Dec 1 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
    Nov 16 Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
    Nov 6 Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
    Oct 20 Akari Therapeutics files to sell 1.29B shares for holders
    See more AKTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.5
    52 Week Low 1.0775
    Average Volume 12,853
    200-Day Moving Average 3.08
    50-Day Moving Average 1.94
    20-Day Moving Average 1.48
    10-Day Moving Average 1.24
    Average True Range 0.16
    RSI (14) 29.08
    ADX 68.89
    +DI 2.54
    -DI 32.11
    Chandelier Exit (Long, 3 ATRs) 1.51
    Chandelier Exit (Short, 3 ATRs) 1.55
    Upper Bollinger Bands 2.04
    Lower Bollinger Band 0.92
    Percent B (%b) 0.26
    BandWidth 75.19
    MACD Line -0.25
    MACD Signal Line -0.24
    MACD Histogram -0.0059
    Fundamentals Value
    Market Cap 6.84 Million
    Num Shares 5.65 Million
    EPS -2.52
    Price-to-Earnings (P/E) Ratio -0.48
    Price-to-Sales 0.00
    Price-to-Book 4.88
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.38
    Resistance 3 (R3) 1.37 1.30 1.35
    Resistance 2 (R2) 1.30 1.25 1.30 1.34
    Resistance 1 (R1) 1.25 1.23 1.28 1.27 1.33
    Pivot Point 1.18 1.18 1.19 1.19 1.18
    Support 1 (S1) 1.14 1.14 1.16 1.15 1.09
    Support 2 (S2) 1.07 1.11 1.07 1.08
    Support 3 (S3) 1.02 1.07 1.07
    Support 4 (S4) 1.04